Mayara Karla dos Santos Nunes

Dr. Mayara Karla dos Santos Nunes

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MNMayara Karla dos Santos Nunes
Mayara Karla dos Santos Nunes
Alexandre SilvaAlexandre Silva
Alexandre Silva
IEIsabella Wanderley de Queiroga Evangelista
Isabella Wanderley de Queiroga Evangelista
JFJoão Modesto Filho
João Modesto Filho
CGCecília Neta Alves Pegado Gomes
Cecília Neta Alves Pegado Gomes
DPDARLENE CAMATI PERSUHN
DARLENE CAMATI PERSUHN
DNA methylation is an epigenetic mechanism for regulating the transcription of many genes and has been linked to the development of various diseases. A promising gene to investigate is methylenetetrahydrofolate reductase (MTHFR), since the enzyme methylenetetrahydrofolate reductase (MTHFR) promotes methyl radical synthesis in the homocysteine cycle and can provide methyl groups for DNA methylation. In addition, several studies have correlated gene polymorphisms of this enzyme with a greater risk of diabetes, but little is known regarding the relationship between epigenetic changes in this gene and diabetes and its complications. The aim of this study was to investigate the relationship between methylation profile in the MTHFR gene promoter and biochemical, inflammatory and oxidative stress markers in individuals with type 2 diabetes (T2DM) who have been diagnosed for 5–10 years with or without diabetic retinopathy (DR) and nephropathy (DN). Specific PCR for methylation (MSP) was used to analyze MTHFR methylation profile in leucocytes DNA. Biochemical markers (glycemia, glycated hemoglobin, total cholesterol, LDL, HDL, triglycerides, serum creatinine), inflammatory markers (C-reactive protein and alpha-1 acid glycoprotein) and oxidative stress (total antioxidant and malonaldehyde) were determined in peripheric blood samples and microalbuminuria in 24 h urine samples. The X2 and Mann–Whitney statistical tests were performed and p < 0.05 were considered significant. The hypermethylated profile was most frequently observed in individuals with retinopathy (p < 0.01) and was associated with higher total cholesterol and LDL levels (p = 0.0046, 0.0267, respectively). Individuals with DN and hypermethylated profiles had higher levels of alpha-1 acid glycoprotein (p = 0.0080) and total antioxidant capacity (p = 0.0169) compared to subjects without complications. Hypermethylation in the promoter of the MTHFR gene is associated with the occurrence of DR and with biochemical, inflammatory and oxidative stress parameters in the context of chronic complications

15 January 2019 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
HBHerlanny Santana Bezerra
Herlanny Santana Bezerra
CACaroline Severo de Assis
Caroline Severo de Assis
MNMayara Karla dos Santos Nunes
Mayara Karla dos Santos Nunes
IEIsabella Wanderley de Queiroga Evangelista
Isabella Wanderley de Queiroga Evangelista
JFJoão Modesto Filho
João Modesto Filho
DPDARLENE CAMATI PERSUHN
DARLENE CAMATI PERSUHN
Polymorphisms in the gene encoding methylenetetrahydrofolate reductase (MTHFR) have been investigated as risk factors for microvascular complications of diabetes; however, simultaneous analysis of these polymorphisms and the methylation pattern of the gene has never been conducted. The objective of the present study was to evaluate the simultaneous relationship between MTHFR methylation and MTHFR C6TT7 and A1298C polymorphisms with metabolic, inflammatory and oxidative stress parameters related to microvascular complications, diabetic retinopathy (DR) and diabetic nephropathy (DN) in diabetic patients. A total of 107 patients who were diagnosed in the previous 5 to 10 years were recruited and divided into groups with complications (DR and/or DN) or without complications. Methylation analysis of the gene promoter was conducted using the MSP technique, and analysis of the A1298C and C677T polymorphisms was conducted using the restriction fragment length polymorphism (RFLP) assay. Microalbuminuria was determined using urine samples, and other analytes of interest were determined in blood samples using commercial kits. The Mann–Whitney and Chi square statistical tests were used with significance considered at p < 0.05. Subjects with a hypermethylated profile and the 1298AA genotype showed the highest levels of blood glucose (p = 0.03), total cholesterol (p = 0.0001) and LDL cholesterol (p = 0.0006). The same profile was associated with higher levels of HbA1c (p = 0.025), glycemia (p = 0.04) and total cholesterol (0.004) in the control group and total cholesterol (p = 0.005) and LDL cholesterol (p = 0.002) in the complications group. Serum creatinine was higher in subjects in the hypermethylated group with the genotype 677CC only in the control group (p = 0.0020). The methylated profile in presence of 677CC + 1298AA and the 677CT/TT +1298AA haplotypes showed higher levels of total cholesterol (p = 0.0024; 0.0031) and LDL cholesterol (p = 0.0060; 0.0125) than 1298AC/CC carriers. The fasting glycemia was higher in hypermethylated profile in the presence of 677CC/1298AA haplotype (p = 0.0077). The hypermethylated methylation profile associated with the 1298AA genotype appeared to be connected to higher values of glycemia, total cholesterol and LDL cholesterol.

11 July 2018 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
Rafaella Cristhine Pordeus LunaRafaella Cristhine Pordeus Luna
Rafaella Cristhine Pordeus Luna
MNMayara Karla dos Santos Nunes
Mayara Karla dos Santos Nunes
MMMussara Gomes Cavalcante Alves Monteiro
Mussara Gomes Cavalcante Alves Monteiro
CSCássia Surama Oliveira Da Silva
Cássia Surama Oliveira Da Silva
RNRayner Anderson Ferreira Do Nascimento
Rayner Anderson Ferreira Do Nascimento
MCMaria José de Carvalho Costa
Maria José de Carvalho Costa
Excess weight is a strong risk factor for the development of dysglycaemia. It has been suggested that changes in the metabolism microRNAs, small non-coding RNAs that regulate gene expression, could precede late glycaemic changes. Vitamin E in turn may exert important functions in methylation and gene expression processes. This study aimed to determine the effect of α-tocopherol on glycaemic variables and miR-9-1 and miR-9-3 promoter DNA methylation in overweight women. A randomized, double-blind, exploratory, placebo-controlled study was conducted in overweight and obese adult women (n = 44) who ingested synthetic vitamin E (all-rac-α-tocopherol), natural source vitamin E (RRR-rac-α-tocopherol) or placebo capsules and were followed up for a period of 8 weeks. Supplemented groups also received dietary guidance for an energy-restricted diet. An additional group that received no supplementation and did not follow an energy-restricted diet was also followed up. The intervention effect was evaluated by DNA methylation levels (quantitative real-time PCR assay) and anthropometric and biochemical variables (fasting plasma glucose, haemoglobin A1C, insulin, and vitamin E). Increased methylation levels of the miR-9-3 promoter region (P < 0.001) and reduced haemoglobin A1C (P < 0.05) were observed in the natural source vitamin E group after intervention. Increased fasting plasma glucose was observed in the synthetic vitamin E group, despite the significant reduction of anthropometric variables compared to the other groups. α-Tocopherol from natural sources increased methylation levels of the miR-9-3 promoter region and reduced haemoglobin A1C in overweight women following an energy-restricted diet. These results provide novel information about the influence of vitamin E on DNA methylation. ClinicalTrials.gov , NCT02922491 . Registered 4 October, 2016.

1 June 2018 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
MNMayara Karla dos Santos Nunes
Mayara Karla dos Santos Nunes
Alexandre SilvaAlexandre Silva
Alexandre Silva
IEIsabella Wanderley de Queiroga Evangelista
Isabella Wanderley de Queiroga Evangelista
JFJoão Modesto Filho
João Modesto Filho
CGCecília Neta Alves Pegado Gomes
Cecília Neta Alves Pegado Gomes
DPDARLENE CAMATI PERSUHN
DARLENE CAMATI PERSUHN

15 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MAMaria Elaine Araruna
Maria Elaine Araruna
EJEdvaldo Balbino Alves Júnior
Edvaldo Balbino Alves Júnior
CSCatarina Alves de Lima Serafim
Catarina Alves de Lima Serafim
MPMatheus Marley Bezerra Pessoa
Matheus Marley Bezerra Pessoa
MPMichelle Liz de Souza Pessôa
Michelle Liz de Souza Pessôa
LBLeônia Maria Batista
Leônia Maria Batista
Background: (-)-Fenchone is a naturally occurring monoterpene found in the essential oils of Foeniculum vulgare Mill., Thuja occidentalis L., and Peumus boldus Molina. Pharmacological studies have reported its antinociceptive, antimicrobial, anti-inflammatory, antidiarrheal, and antioxidant activities. Methods: The preventive antiulcer effects of (-)-Fenchone were assessed through oral pretreatment in cysteamine-induced duodenal lesion models. Gastric healing, the underlying mechanisms, and toxicity after repeated doses were evaluated using the acetic acid-induced gastric ulcer rat model with oral treatment administered for 14 days. Results: In the cysteamine-induced duodenal ulcer model, fenchone (37.5–300 mg/kg) significantly decreased the ulcer area and prevented lesion formation. In the acetic acid-induced ulcer model, fenchone (150 mg/kg) reduced (p < 0.001) ulcerative injury. These effects were associated with increased levels of reduced glutathione (GSH), superoxide dismutase (SOD), interleukin (IL)-10, and transforming growth factor-beta (TGF-β). Furthermore, treatment with (-)-Fenchone (150 mg/kg) significantly reduced (p < 0.001) malondialdehyde (MDA), myeloperoxidase (MPO), interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and nuclear transcription factor kappa B (NF-κB). A 14-day oral toxicity investigation revealed no alterations in heart, liver, spleen, or kidney weight, nor in the biochemical and hematological parameters assessed. (-)-Fenchone protected animals from body weight loss while maintaining feed and water intake. Conclusion: (-)-Fenchone exhibits low toxicity, prevents duodenal ulcers, and enhances gastric healing activities. Antioxidant and immunomodulatory properties appear to be involved in its therapeutic effects.

1 July 2021 in Current Diabetes Reviews
Verified
Journal Article
Open access
PDF file
CACaroline Severo de Assis
Caroline Severo de Assis
Alexandre SilvaAlexandre Silva
Alexandre Silva
MNMayara Karla dos Santos Nunes
Mayara Karla dos Santos Nunes
JFJoão Modesto Filho
João Modesto Filho
RNRayner Anderson Ferreira Do Nascimento
Rayner Anderson Ferreira Do Nascimento
DPDARLENE CAMATI PERSUHN
DARLENE CAMATI PERSUHN
Aims: Analysis of the relationship between the methylation profile of miR-9-1 or miRs -9-1 / -9-3 and diabetic retinopathy. Background: Diabetic Retinopathy (DR) is a frequent complication of Diabetes mellitus and it has a decisive impact on the quality of life, as it is one of the biggest causes of blindness in the adult population. Levels of microRNA-9 have been shown to be related to diabetes but little is known about its involvement with DR in humans. Objective: To analyze the relationship between the methylation profile of miR-9-1 or miRs -9-1/-9-3 and DR. Methods: 103 patients diagnosed with diabetes for 5 to 10 years were analyzed. The data were categorized according to clinical, biochemical, lifestyle and anthropometric parameters. DNA extracted from leukocyte samples was used to determine the methylation profile of miRs-9-1 and -9-3 using a specific methylation PCR assay. Results: miR-9-1 methylation was related to diabetic retinopathy, indicating that methylation of this miR increases the chances of presenting retinopathy up to 5 times. In our analyses, diabetics with lower levels of creatinine and CRP showed significant reductions (99% and 97%) in presenting DR. Methylation of both miRs-9-1 and 9-3 methylated increases the chances of presenting DR by 8 times; in addition, a sedentary lifestyle can increase the risk for the same complication by up to 6 times. Conclusion: Our results suggest that both methylation of miR-9-1 and e miRs-9-1 / 9-3 favors DR in patients with diabetes in a period of 5 to 10 years of diagnosis.